title: Paclitaxel, carboplatin, and hexamethyl-melamine (taxchex) as first-line therapy for ovarian cancer.
abstract: BACKGROUND
  The addition of hexamethylmelamine to therapy with cisplatin, cyclophosphamide, and doxorubicin significantly enhanced outcomes of patients with advanced ovarian cancer. Hexamethylmelamine, also known as altretamine, has potent antineoplastic activity when used as a single agent in patients who have failed to respond to both platinum-based and paclitaxel therapy. We have conducted a pilot study to evaluate the efficacy and safety of adding this drug to the popular ovarian cancer regimen of paclitaxel plus carboplatin.
  
  
  METHODS
  Patients with advanced ovarian, fallopian tube, or primary peritoneal cancer (International Federation of Gynecology and Obstetrics stages IIA, IIIC, and IV) were prospectively enrolled to receive six cycles, repeated every 4 weeks, of paclitaxel (150 mg/m2 i.v., day 1), carboplatin (AUC 5.0 i.v., day 1), and hexamethylmelamine (150 mg/m2 p.o., days 2-15). Colony stimulating factors were prohibited. Response and toxicity were monitored by use of Eastern Cooperative Oncology Group criteria.
  
  
  RESULTS
  Twenty patients were enrolled, 18 with ovarian cancer, one with fallopian tube cancer, and one with peritoneal cancer; 17 of these patients were evaluable for response and toxicity. At a median follow-up of 6.5 months, 13 of the patients had a complete response (76%), and four had progressive disease. Three of those with a complete response had a recurrence within 1 year of completing treatment. Toxicity was acceptable, with myelosuppression the most severe adverse effect; one patient had grade 3 anemia, one patient had grade 4 thrombocytopenia, and 12 patients had grade 4 neutropenia. Quality of life showed improvement over the course of therapy, particularly in the physical well-being subscale.
  
  
  CONCLUSIONS
  The addition of hexamethylmelamine to paclitaxel and carboplatin is a well-tolerated multidrug combination for women with advanced ovarian cancer that deserves further testing in a phase III study.
authors.affiliation: University of Wisconsin, Madison Comprehensive Cancer Center, USA.
authors.forename: E M
authors.initials: EM
authors.lastname: Hartenbach
authors.forename: L S
authors.initials: LS
authors.lastname: Harris
authors.forename: H H
authors.initials: HH
authors.lastname: Bailey
authors.forename: E A
authors.initials: EA
authors.lastname: Grosen
authors.forename: E
authors.initials: E
authors.lastname: Larrison
authors.forename: D
authors.initials: D
authors.lastname: Chen
authors.forename: L B
authors.initials: LB
authors.lastname: Twiggs
authors.forename: J C
authors.initials: JC
authors.lastname: Schink
mesh_terms: D000328:Adult; D000368:Aged; D006585:Altretamine / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000523:psychology; D017239:Paclitaxel / Q000008:administration & dosage; D010865:Pilot Projects; D011446:Prospective Studies; D011788:Quality of Life
chemical_list: D016190:Carboplatin; D017239:Paclitaxel; D006585:Altretamine